IncellDx’s patented cell-based molecular diagnostics platform

[Guest guest]

http://www.businesswire.com/news/home/20101202005782/en/IncellDx-Named-2010-Biot\

ech-Company-Year

December 02, 2010 10:06 AM Eastern Time

IncellDx Named 2010 Biotech Company of the Year

MENLO PARK, Calif.--(BUSINESS WIRE)--IncellDx, Inc. was named the 2010 Biotech

Winner in the fifth annual Emerging Technologies Competition sponsored by the

Silicon Valley / San Business Journal at a ceremony Tuesday evening in

Mountain View, CA.

“We are elated and proud to win such a prestigious award in a category that is

vital to improving healthcare worldwide,” commented Dr. Bruce , CEO of

IncellDx. “Winning a biotech award in Silicon Valley is a dream for any

innovator. Achieving this kind of recognition can only be realized with the

backing of an exceptional team and committed investors.”

IncellDx’s patented cell-based molecular diagnostics platform allows for the

simultaneous detection of proteins and genes in intact cells from patient

samples. This revolutionary technology promises to bring personalized medicine

to infectious disease testing.

Current laboratory tests can only detect the presence of viral diseases, not how

they are actually working inside the body. IncellDx's method uses molecular

probes in combination with automated cellular analysis to accurately assess how

viral infections like HPV, HIV, and hepatitis are behaving differently in each

patient.

This information allows infectious diseases to be more definitively diagnosed

and then localized on a cellular level. Patient and cell-specific therapies can

then be targeted on these infections for maximum efficacy and with minimal side

effects. Ultimately this personalized medicine approach to diagnosing infectious

diseases is much more accurate and cost effective than traditional methods. It

has the power to radically transform the way healthcare for cervical cancer and

AIDS is delivered. IncellDx diagnostic products are currently available in the

European Union.

IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and

monitoring of life threatening viral diseases in the areas of cervical cancer,

HIV/AIDS, hepatitis, and organ transplant rejection. The company is privately

held and located in Menlo Park, California. The company is currently raising a

Series B round of funding to finance its first FDA clinical trial.

Contacts

IncellDx, Inc.

Hass, 1-650-777-7630

www.incelldx.com

[Guest guest]

http://www.businesswire.com/news/home/20101202005782/en/IncellDx-Named-2010-Biot\

ech-Company-Year

December 02, 2010 10:06 AM Eastern Time

IncellDx Named 2010 Biotech Company of the Year

MENLO PARK, Calif.--(BUSINESS WIRE)--IncellDx, Inc. was named the 2010 Biotech

Winner in the fifth annual Emerging Technologies Competition sponsored by the

Silicon Valley / San Business Journal at a ceremony Tuesday evening in

Mountain View, CA.

“We are elated and proud to win such a prestigious award in a category that is

vital to improving healthcare worldwide,” commented Dr. Bruce , CEO of

IncellDx. “Winning a biotech award in Silicon Valley is a dream for any

innovator. Achieving this kind of recognition can only be realized with the

backing of an exceptional team and committed investors.”

IncellDx’s patented cell-based molecular diagnostics platform allows for the

simultaneous detection of proteins and genes in intact cells from patient

samples. This revolutionary technology promises to bring personalized medicine

to infectious disease testing.

Current laboratory tests can only detect the presence of viral diseases, not how

they are actually working inside the body. IncellDx's method uses molecular

probes in combination with automated cellular analysis to accurately assess how

viral infections like HPV, HIV, and hepatitis are behaving differently in each

patient.

This information allows infectious diseases to be more definitively diagnosed

and then localized on a cellular level. Patient and cell-specific therapies can

then be targeted on these infections for maximum efficacy and with minimal side

effects. Ultimately this personalized medicine approach to diagnosing infectious

diseases is much more accurate and cost effective than traditional methods. It

has the power to radically transform the way healthcare for cervical cancer and

AIDS is delivered. IncellDx diagnostic products are currently available in the

European Union.

IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and

monitoring of life threatening viral diseases in the areas of cervical cancer,

HIV/AIDS, hepatitis, and organ transplant rejection. The company is privately

held and located in Menlo Park, California. The company is currently raising a

Series B round of funding to finance its first FDA clinical trial.

Contacts

IncellDx, Inc.

Hass, 1-650-777-7630

www.incelldx.com